Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.48 |
| ▸ | CA1 | P00915 | 12/20 | 0.48 |
| ▸ | CA4 | P22748 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 10/20 | 0.44 |
| ▸ | CA12 | O43570 | 9/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7018333 | 1.00 | CA2 (0.48) | CA2CA1CA4CA7ALDH1A1 | |
| SCHEMBL7022411 | 0.86 | CA1 (0.51) | CA2CA1CA4CA7CA9 | |
| SCHEMBL7022408 | 0.86 | CA1 (0.51) | CA2CA1CA4CA7CA9 | |
| SCHEMBL7032505 | 0.86 | SLC9A3 (0.51) | — | |
| SCHEMBL7032499 | 0.86 | SLC9A3 (0.51) | — | |
| SCHEMBL19341340 | 0.80 | CA1 (0.43) | CA2CA1CA4CA7ALDH1A1 | |
| SCHEMBL1277409 | 0.79 | ALDH1A1 (0.36) | CA2CA1CA4CA7ALDH1A1 | |
| SCHEMBL1277449 | 0.77 | CA1 (0.35) | CA2CA1CA4CA7ALDH1A1 | |
| SCHEMBL7030195 | 0.76 | CA1 (0.44) | CA2CA1CA4CA9CA12 | |
| SCHEMBL7030194 | 0.76 | CA1 (0.44) | CA2CA1CA4CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322602-A1 | SUBSTITUTED CINNAMIC ACID GUANIDIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT, AND TO A MEDICAMENT CONTAINING THESE COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2003-07-02 | — | — | EP | disclosed |
| US-6399824-B1 | FOR THERAPY AND PROPHYLAXIS OF ARRHYTHMIAS, CARDIAC INFRACTION, ISCHEMIC CONDITIONS, ANGINA PECTORIS, SHOCK, FOR PRESERVING AND STORING A TRANSPLANT FOR SURGICAL MEASURE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-04 | — | — | US | disclosed |
| US-20020058710-A1 | SUBSTITUTED CINNAMIC, ACID GUANIDIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, AND MEDICAMENT COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH. | 2002-05-16 | — | — | US | disclosed |
| WO-2002024637-A1 | SUBSTITUTED CINNAMIC ACID GUANIDIDES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT, AND TO A MEDICAMENT CONTAINING THESE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058710-A1 | SUBSTITUTED CINNAMIC, ACID GUANIDIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, AND MEDICAMENT COMPRISING THEM | GANC, GMPS, GCDH | CA2 608/4885CA1 2872/4885CA4 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.